Cognitive Enhancement

N-Acetyl Selank

An acetylated form of Selank with enhanced CNS penetration and bioavailability - producing anxiolytic, nootropic, and immune-modulatory effects via GABA and BDNF pathways.

C₃₃H₅₇N₉O₁₀Half-life: ~2-3 hours (improved vs. Selank)Molar mass: 757.86 g/mol

⚠ Research & Educational Use Only. N-Acetyl Selank is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Medically reviewed by Dr. Amanda Reid, MDWritten by the KnowYourPeptide Research TeamLast updated April 2026
Our editorial standards →
Key Takeaways
  • Enhanced bioavailability compared to native Selank - the N-acetyl modification improves stability and CNS penetration
  • Anxiolytic effects without sedation or addiction potential - superior to benzodiazepines in this regard
  • Enhances cognitive performance: working memory, learning speed, focus, and information processing
  • N-Acetyl Selank is not FDA-approved for human use. It is a research chemical for scientific study only.

Research At a Glance

  • Enhanced bioavailability compared to native Selank - the N-acetyl modification improves stability and CNS penetration
  • Anxiolytic effects without sedation or addiction potential - superior to benzodiazepines in this regard
  • Enhances cognitive performance: working memory, learning speed, focus, and information processing
  • BDNF upregulation - promotes neuroplasticity and neuroprotection
Calculate N-Acetyl Selank dose

What is N-Acetyl Selank?

N-Acetyl Selank is an acetylated analogue of Selank - itself a synthetic heptapeptide derived from the endogenous immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg) with a Gly-Glu-Pro extension added to improve stability. The N-acetyl modification at the peptide's amino terminus further enhances stability against aminopeptidase enzymes and improves lipophilicity, which may enhance blood-brain barrier penetration and CNS bioavailability.

Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic research compound with a superior safety profile compared to classical benzodiazepines. The challenge with benzodiazepines - GABA-A receptor positive allosteric modulators - is their potential for tolerance, dependence, and cognitive impairment. Selank's anxiolytic mechanism is multifactorial and includes GABA pathway modulation without direct benzodiazepine receptor binding, potentially achieving anxiolysis with less risk of dependence.

The mechanism of Selank and N-Acetyl Selank involves multiple targets: modulation of GABAergic transmission (the primary inhibitory neurotransmitter system), upregulation of BDNF (Brain-Derived Neurotrophic Factor, which promotes neuroplasticity and neuroprotection), regulation of serotonin metabolism, and effects on the enkephalinase enzyme system (which degrades endogenous opioid peptides). This multi-target profile may explain why Selank produces both anxiolytic and cognitive-enhancing effects simultaneously - many anxiolytics impair cognition by broadly suppressing CNS activity, but Selank appears to reduce anxiety while maintaining or improving cognitive performance.

The immunomodulatory properties of Selank are inherited from its Tuftsin-derived core. Tuftsin is a naturally occurring tetrapeptide produced from immunoglobulin G (IgG) that activates macrophages and natural killer cells. The inclusion of the Tuftsin-related sequence gives Selank a dual neurological-immune profile that has been studied in the context of stress-induced immunosuppression.

N-Acetyl Selank is often compared to and complementary with N-Acetyl Semax. The two are commonly combined in research protocols targeting anxiety, cognitive performance, and neuroprotection - with Semax providing more stimulating, BDNF-driven nootropic effects and Selank providing the calming, anxiety-reducing component.

Key Research Benefits

Documented effects observed in preclinical and clinical studies on N-Acetyl Selank. See all Cognitive Enhancement peptides for comparison.

Enhanced bioavailability compared to native Selank - the N-acetyl modification improves stability and CNS penetration
Anxiolytic effects without sedation or addiction potential - superior to benzodiazepines in this regard
Enhances cognitive performance: working memory, learning speed, focus, and information processing
BDNF upregulation - promotes neuroplasticity and neuroprotection
Modulates GABAergic signalling - the primary inhibitory neurotransmitter system
Anti-inflammatory properties through cytokine regulation
Improves immune balance - the heptapeptide component has immunomodulatory properties
May reduce depression alongside anxiety in research models

Common Stacks

N-Acetyl Selank is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.

BPC-157's tissue healing and gut-protective effects complement Thymosin Alpha-1's immune activation for comprehensive recovery and immune support.

BPC-157 profile

Both are anti-inflammatory peptides with complementary mechanisms: Thymosin Alpha-1 via T cell activation, VIP via cytokine suppression.

VIP profile

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.

Mild fatigue and lethargy at higher doses due to GABAergic activity
Nasal irritation if administered intranasally
Occasional headache during adjustment period
Generally very well tolerated in published studies

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

N-Acetyl Selank is typically dosed at 250-750 mcg per day, via subcutaneous injection or intranasal spray.

Standard research dose: 250-500 mcg per day Intranasal dose: 2-3 drops per nostril, 2-3 times daily (at 0.15% solution) Cycle: 2-4 weeks on, 1-2 weeks off to maintain sensitivity Often compared to and combined with N-Acetyl Semax for complementary anxiolytic + cognitive enhancement

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

For injection: reconstitute with bacteriostatic water, administer subcutaneously once daily. For intranasal: use a 0.15% solution nasal spray, 2-3 sprays per nostril, 2-3 times per day. Intranasal administration offers convenient, injection-free dosing with good bioavailability.

Explore Further

Quick Reference

Half-Life
~2-3 hours (improved vs. Selank)
Molar Mass
757.86 g/mol
Formula
C₃₃H₅₇N₉O₁₀
Legal Status
Research chemical. Not approved for human use in Western countries. Available as prescription medication in Russia.
Storage
Lyophilised/dry: refrigerate at 2-8 degrees C. Intranasal solution: refrigerate, use within 30 days of reconstitution.

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.